Shire’s potential blockbuster Xiidra (lifitegrast) has been approved in the US for dry eye disease, bouncing back from a rejection by the regulator late last year. Xiidra, in a 5% solution ...
Novartis paid Takeda $3.4 billion for its FDA-approved dry eye drug Xiidra during the Japanese pharma’s merger with Shire in 2019, outlining the sales potential in this market niche. But with ...
If underlying inflammation is present, the prescription eye drop XIIDRA® (lifitegrast ophthalmic solution) 5%, used to treat the signs and symptoms of chronic dry eye by targeting inflammation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results